Boston - Advanced technologies are helping researchers identify environmental contaminants that could potentially be contributing to the rising incidence of early-onset colorectal cancer. However, epigenetic studies on such associations should be interpreted with caution, according to researchers at Dana-Farber Cancer Institute , who are leading experts in the disease.
In a Perspective published today in Nature Medicine , the authors comment on a study in the same issue, which found an association between early-onset colorectal cancer and exposure to certain pesticides, particularly an herbicide called picloram. The study was led by researchers at the Vall d’Hebron Institute of Oncology in Barcelona, Spain.
“There is something in our environment that is likely contributing to early-onset colorectal cancer, and we now have innovative tools and technologies to be able to study this in new ways,” says Dr. Kimmie Ng , director of the Young-Onset Colorectal Cancer Center at Dana-Farber and senior author of the Perspective piece. “But in order to conclude that something is a risk factor, we need proof of causality and a biological mechanism.”
While the incidence of colorectal cancer has decreased in recent decades among older adults in Western countries with screening programs for colorectal cancer, it’s been on the rise among young adults under the age of 50. Epidemiological studies have suggested a birth cohort effect, where individuals born in the 1960s and beyond, who share common lifestyle and environmental exposures, are experiencing progressively higher rates of the disease across successive generations.
Epigenetics is the study of how our environment modifies gene activity. Epigenetic analyses of the exposome, which is the totality of environmental exposures an individual has encountered from conception and across their lifetime, are offering new insights into potential links between environmental exposures and the risk of early-onset colorectal cancer.
In the Perspective paper, Drs. Ng, David J. Lee , and Sylvan C. Baca point out several caveats to the study, which analyzed molecular fingerprints, or patterns of genomic modifications in response to environmental factors, and their association with early-onset colorectal cancer. Dr. Lee is a Hematology/Oncology Fellow at Dana-Farber. Dr. Baca is a medical oncologist at Dana-Farber.
Dr. Ng noted that the study relied on self-reported data on pesticide use, which may not be accurate. In addition, the population studied was restricted to male individuals of European ancestry, which could make the results less generalizable to the broader population. Finally, it’s difficult to measure exposure to pesticides, such as the timing of the exposure, the duration of the exposure, and how the exposure relates to the molecular fingerprints observed.
“Many unknowns remain about whether and how picloram actually causes early-onset colorectal cancer,” said Dr. Lee, first author of the Perspective piece. “We are many steps removed from confirming that this is a risk factor for colorectal cancer, but I think what is novel and interesting is the approach the authors took to assess for various environmental exposures in patients with colorectal cancer.”
Despite the study’s limitations, Dr. Ng and her coauthors say that it offers optimism that new epigenetic approaches, such as molecular fingerprinting, can help uncover new risk factors for early-onset colorectal cancer and help guide strategies for prevention.
Dana-Farber is at the cutting edge of research into early-onset colorectal cancer. Dr. Ng and her colleagues in the Young-Onset Colorectal Cancer Center are identifying risk factors and developing of new therapies for colorectal cancer in young adults. The Beyond CRC Project is a research study enrolling young adults with colorectal cancer. For more information, visit the Young-Onset Colorectal Cancer Center .
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,200 clinical trials.
###
Nature Medicine
Uncovering risk factors in the exposome for early-onset colorectal cancer
30-Apr-2026